2024
W35 Nicotine Use and Metabotropic Glutamate Receptor 5 (mGluR5) in Individuals With Major Depressive and Post Traumatic Stress Disorders
Baldassarri S, Asch R, Hillmer A, Pietrzak R, DellaGioia N, Esterlis I, Davis M. W35 Nicotine Use and Metabotropic Glutamate Receptor 5 (mGluR5) in Individuals With Major Depressive and Post Traumatic Stress Disorders. Drug And Alcohol Dependence 2024, 260: 110653. DOI: 10.1016/j.drugalcdep.2023.110653.Peer-Reviewed Original Research
2023
Examining mGlu5 Receptor Availability as a Predictor of Vulnerability to PTSD: An [18F]FPEB and PET Study in Male and Female Rats
Asch R, Fowles K, Pietrzak R, Taylor J, Esterlis I. Examining mGlu5 Receptor Availability as a Predictor of Vulnerability to PTSD: An [18F]FPEB and PET Study in Male and Female Rats. Chronic Stress 2023, 7: 24705470231215001. PMID: 38024327, PMCID: PMC10666551, DOI: 10.1177/24705470231215001.Peer-Reviewed Original ResearchPost-traumatic stress disorderReceptor availabilityFemale ratsPathophysiology of PTSDFootshock exposureMetabotropic glutamate receptor 5Recent preclinical findingsGlutamate receptor 5Positron emission tomographyPreclinical findingsClinical findingsFe ratsReceptor 5Lower baselineEmission tomographyGreater riskPET studiesRatsStress disorderDifferential involvementPassive copingSex differencesMalesPTSD susceptibilityBaseline
2020
Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression
Dai D, Lacadie CM, Holmes SE, Cool R, Anticevic A, Averill C, Abdallah C, Esterlis I. Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression. Chronic Stress 2020, 4: 2470547020980681. PMID: 33426409, PMCID: PMC7758564, DOI: 10.1177/2470547020980681.Peer-Reviewed Original ResearchMajor depressive disorderPost-traumatic stress disorderMagnetic resonance imagingAcute ketamine administrationKetamine administrationKetamine infusionMDD subjectsInferior frontal gyrusComorbid post-traumatic stress disorderPTSD groupAcute ketamine treatmentFrontal gyrusHealthy control subjectsIntravenous ketamine infusionRegional volume differencesImpact of ketamineSingle ketamine infusionStructural alterationsFuture therapeutic targetsVoxel-wise t-testsKetamine treatmentControl subjectsDepressive disorderHC groupPTSD subjects